Nuraleve Receives CE Mark Approval
Nuraleve is proud to announce that on August 10th 2015, our Neurostimulator has been approved for the following indications in the European market:
- Chronic Pain
- Addiction Reduction (including smoking)
- Post-stroke Rehabilitation
- Cognitive deficits (including those related to decision making)
This CE mark approval expands the markets where Nuraleve products are available, and represents a major milestone in the go-to-market strategy set out by the board of directors in 2013.